2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldehyde Dehydrogenase (ALDH)
  5. ALDH3 Isoform

ALDH3

ALDH3A1 (aldehyde dehydrogenase 3A1) is a cytoplasmic NAD(P)+-dependent enzyme that oxidizes medium-chain aliphatic and aromatic aldehydes into their corresponding carboxylic acids, thereby supporting cellular aldehyde detoxification and antioxidant defense mechanisms[1][2]. Mechanistically, ALDH3A1 removes reactive aldehydes generated during lipid peroxidation and environmental stress exposure, limiting oxidative damage and contributing to cellular homeostasis in tissues such as the cornea, lung, skin, bladder, and stomach that are continuously exposed to exogenous stressors[1][3]. In disease-associated models, ALDH3A1 regulates oxidative stress resistance and DNA damage responses, and its deficiency increases susceptibility to tissue injury, including corneal edema and clouding under physiological and ultraviolet stress conditions[1]. ALDH3A1 expression is also elevated in several malignancies, including gastric, lung, and prostate cancers, where it has been associated with cancer stem cell phenotypes, tumorigenesis, and therapeutic resistance[1][4]. Compared with related aldehyde dehydrogenase isoforms, ALDH3A1 shares less than 50% sequence similarity with ALDH1A1, supporting the development of isoform-selective pharmacological tools despite the conserved catalytic architecture of the ALDH family[5]. For experimental applications, selective ALDH3A1 inhibitors, including benzimidazole-derived compounds, have been developed to enhance cyclophosphamide or mafosfamide cytotoxicity in ALDH3A1-expressing cancer cells, providing a strategy for investigating ALDH3A1-mediated chemoresistance mechanisms[1][6].

ALDH3 Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-125085
    ALDH3A1-IN-3
    		Inhibitor 99.43%
    ALDH3A1-IN-3 (CB29) is a selective inhibitor of ALDH3A1, with a Ki value of 4.7 μM and an IC50 value of 16 μM. ALDH3A1-IN-3 has no inhibitory potential on the in vitro activity of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2. ALDH3A1-IN-3 can be used in cellular oxidation and cancer research.
  • HY-B0364A
    Dyclonine hydrochloride
    		Inhibitor 99.30%
    Dyclonine (Dyclocaine) hydrochloride is an orally effective ALDH covalent inhibitor (crosses blood-brain barrier), with an IC50 of 35 μM for ALDH2 and 76 μM for ALDH3A1. Dyclonine hydrochloride has sensitizing activities for targeted cancer cells and antibacterial. Dyclonine hydrochloride is also a local agent that can suppress or relieve pain. that blocks the transmission of various nerve impulses or stimuli and inhibits the sensation of touch and pain.
  • HY-144670
    ALDH3A1-IN-1
    		Inhibitor 99.85%
    ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel.
  • HY-146683
    KS106
    		Inhibitor 99.87%
    KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase.
  • HY-128299
    ALDH3A1-IN-4
    		Inhibitor 99.91%
    ALDH3A1-IN-4 is a selective ALDH3A1 inhibitor with an IC50 of 0.2 μM. ALDH3A1-IN-4 binds to the aldehyde-binding pocket of ALDH3A1 via hydrophobic interactions and van der Waals forces. ALDH3A1-IN-4 acts as a chemosensitizer that sensitizes ALDH3A1-expressing cancer cells to the antiproliferative effect of mafosfamide, but does not produce a sensitizing effect on non-cancer cells that do not express ALDH3A1. ALDH3A1-IN-4 is applicable to research related to lung adenocarcinoma and glioblastoma.
  • HY-144671
    ALDH3A1-IN-2
    		Inhibitor
    ALDH3A1-IN-2 (Compound 19) is a potent inhibitor of ALDH3A1 with an IC50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH3A1-IN-2 has the potential for the research of cancer diseases.
Cat. No. Product Name / Synonyms Application Reactivity